Transferring a young person’s blood into an older person to stop or slow the aging process may seem like science fiction, but for some, it’s real life.

The Food and Drug Administration announced a safety alert on Tuesday against the use of plasma for treating age-related conditions.

“Simply put, we’re concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies,” the FDA said in a press statement.

The plasma infusions from donors ages 16-25 can cost up to thousands of dollars per infusion, according to CNN.

While the blood transfer is typically done to reverse aging or memory loss, others have used it to treat such conditions as dementia, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, heart disease or post‐traumatic stress disorder, Bloomberg reports.

Despite piquing the interest of technology entrepreneurs like billionaire Peter Thiel, the FDA says, “There is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat or prevent these conditions, and there are risks associated with the use of any plasma product,” the FDA said in a statement.

Even though plasma infusion is used in trauma scenarios and with patients whose blood doesn’t coagulate, there is risk of complications like lung injury and allergic reactions, according to the FDA.
 
Read more here.